Skip to main content

July 2015

 

 

academics

 

Clinical research courses

Vacancy as IPQA (Quality Manager) in Client of 7 Colors Consultants - Logistic industry

Our client is a Logistics company based out at Chennai

Post: IPQA (Quality Manager) - 2

Career opportunity for Manager OSD (Pharmacist) in GlaxoSmithKline

GlaxoSmithKline Pharmaceuticals Ltd. (GSK Rx India) is one of the oldest pharmaceuticals company and employs over 5000+ people. Globally, we are a £ 27.4 billion, leading, research-based healthcare and pharmaceutical company. In India, we are one of the market leaders. At GSK, our mission is to improve the quality of life by enabling people to do more, feel better and live longer. This mission drives us to make a real difference to the lives of millions of people with our commitment to effective healthcare solutions.

Post: Manager OSD (Pharmacist)

Global Green Nanotechnology Conclave 2015 (GiGaNTiC 2015) by CII

Global Green Nanotechnology Conclave
(GiGaNTiC 2015)
“Fostering Innovation to build core competency and provide market leadership for sustainable growth”
6-7 August 2015
Ahmedabad, India

Nanotechnology offers immense promise for developing new technologies that are more sustainable than current technologies. Global Green Nanotechnology Conclave 2015 will explore the possibilities of Indian industry to take part in the research, innovation, and nanotechnology product development. The conclave will serve to create the business opportunities, awareness and build business linkages among MSME's, large industries, institutions, universities, government and other regulatory bodies. Conclave would be providing a great platform to suppliers of the raw materials, processing and characterization instruments and machinery manufacturers for showcasing new technologies which will enhance the penetration of nanotechnology in India. The aim of this conclave is to facilitate collaborations and foster nano innovation and further commercialization of these technologies to build core competency and provide market leadership for sustainable growth.

The US Food and Drug Administration (FDA) has approved AstraZeneca's Iressa (gefitinib) tablets, 250mg once daily, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.

A new affordable, non-invasive test that detects electrical activity in the brain may predict the risk of Alzheimer's disease, scientists say. The research was published in the Journal of Alzheimer's Disease.

(adsbygoogle = window.adsbygoogle || []).push({});